[Correction: Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results].

[Correction: Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results]. Klin Monbl Augenheilkd. 2016 Sep 6; Authors: Pfau M, Fassnacht-Riederle HM, Freiberg FJ, Wons JB, Wirth M, Becker MD, Michels S PMID: 27599047 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27599047?dopt=Abstract

Source: Klinische Monatsblatter fur Augenheilkunde - September 7, 2016 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

More News: Age-Related Macular Degeneration (AMD) | Avastin | Lucentis | Opthalmology | Ranibizumab Injection